

ASX ANNOUNCEMENT

Benitec's hepatitis C therapeutic selected for oral presentation at HCV 2013 Symposium

Sydney Australia, 15 August 2013: Benitec Biopharma Limited (ASX Code: BLT), today announced that its ddRNAi-based gene silencing program for hepatitis C (HCV) has been selected for an oral presentation at the prestigious International Symposium on Hepatitis C Virus and Related Viruses (HCV 2013) to be held in Melbourne in October.

HCV 2013 is an annual meeting that brings together the best international researchers focusing on the complete spectrum of hepatitis C virus research, including presentations on the latest therapeutic advances.

Benitec will present data on TT-034, its novel gene silencing therapeutic. TT-034, which is expected to enter a first-in-man Phase I/II clinical trial later this year, has the potential to be a one-shot cure for chronic HCV.

This follows Benitec's selection last week, for an oral presentation at another international liver disease conference, the American Association for the Study of Liver Disorders conference, known as "The Liver Meeting". These two selections indicate the growing awareness of, and interest internationally in, Benitec's unique therapeutic approach to the disease.

The company's Senior Vice President R&D, Dr David Suhy, who will deliver the presentation, commented: "We are excited to be selected for an oral presentation at this important Symposium. The invitation is a further endorsement of the growing awareness amongst our scientific peers of TT-034 and the potential the treatment offers for curing this important disease."

According to Symposium's organisers it is the leading international meeting for scientists interested in the molecular virology, pathogenesis, prevention and treatment of hepatitis C virus infections. It has become an important platform for the presentation of new developments in the search for treatments and curative approaches for hepatitis C.

For more information please contact: Dr Peter French | Chief Executive Officer
Phone: +61 (02) 9555 6986 pfrench@benitec.com | www.benitec.com

About TT-034: TT-034 is a potentially transformative therapeutic that is intended to provide a "one-shot-cure" for hepatitis C with a single injection. Preclinical studies have shown that the vector used to deliver TT-034 specifically targets liver cells where it transfects almost every cell without causing toxic effects. TT-034 is designed to prevent development of viral resistance (a major problem for most hepatitis C drugs) by simultaneously silencing three separate highly conserved regions on the virus genome. Studies have demonstrated that a single treatment of TT-034 is active out to 180 days (the duration of the studies).

About Benitec Biopharma Limited: Benitec Biopharma Limited is an ASX-listed biotechnology company (ASX Code: BLT) based in Sydney, Australia. The company has a pipeline of in-house and partnered therapeutic programs based on its patented gene-silencing technology, ddRNAi. Benitec is developing treatments for chronic and life-threatening human conditions such as hepatitis C, hepatitis B, wet age-related macular degeneration, cancer-associated pain, drug resistant lung cancer and oculopharyngeal muscular dystrophy based on this technology. In addition, Benitec has licensed ddRNAi technology to other biopharmaceutical companies who are progressing their programs towards the clinic for applications including HIV/AIDS, retinitis pigmentosa and Huntington's disease. For more information on Benitec refer to the Company's website at www.benitec.com.